Tampa, Fla. — Among molecularly targeted agents being developed to treat melanoma, some of the most exciting are anti-CTLA-4 antibodies now being developed by Pfizer and Medarex.
Prebiotic Skin Care’s Effectiveness in AD for SOC Patients
The Cutaneous Connection: A Reminder of Patient Impact
Derm-Biome and TransBIOtech Awarded $450,000 ARD Grant Funding for Inflammatory Disease and Skin Aging Research
The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment
2 Years of Treatment With Dupilumab Led to Improvements In Symptoms of AD and Comorbid Anxiety, Depression
Understanding Buy and Bill for Medical Dermatology: A Win-Win